Home > Analyse
Actualite financiere : Actualite bourse

Merck: Japan approves Keytruda for urothelial carcinoma.

(CercleFinance.com) - Japan has approved Merck's Keytruda as a treatment for advanced urothelial carcinoma, opening up new options for patients whose disease progresses, the US company said on Tuesday.


More specifically, the drug has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy.

Chemotherapy has long been the standard of care for advanced urothelial carcinoma, but the phase 3 trial demonstrated superior overall survival with Keytruda versus chemotherapy.

With this approval, KeytrudaA is now indicated for use in four types of cancer in Japan, including for the treatment of advanced non-small cell lung cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.